173 related articles for article (PubMed ID: 11967542)
41. The generation of antibody-secreting plasma cells.
Nutt SL; Hodgkin PD; Tarlinton DM; Corcoran LM
Nat Rev Immunol; 2015 Mar; 15(3):160-71. PubMed ID: 25698678
[TBL] [Abstract][Full Text] [Related]
42. Plasma cell differentiation and survival.
Tarlinton D; Radbruch A; Hiepe F; Dörner T
Curr Opin Immunol; 2008 Apr; 20(2):162-9. PubMed ID: 18456483
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant-specific regulation of long-term antibody responses by ZBTB20.
Wang Y; Bhattacharya D
J Exp Med; 2014 May; 211(5):841-56. PubMed ID: 24711582
[TBL] [Abstract][Full Text] [Related]
44. New insights into the ontogeny, diversity, maturation and survival of long-lived plasma cells.
Fooksman DR; Jing Z; Park R
Nat Rev Immunol; 2024 Jul; 24(7):461-470. PubMed ID: 38332373
[TBL] [Abstract][Full Text] [Related]
45. Long-Lived Plasma Cells in Mice and Men.
Brynjolfsson SF; Persson Berg L; Olsen Ekerhult T; Rimkute I; Wick MJ; Mårtensson IL; Grimsholm O
Front Immunol; 2018; 9():2673. PubMed ID: 30505309
[TBL] [Abstract][Full Text] [Related]
46. What is and what should always have been: long-lived plasma cells induced by T cell-independent antigens.
Bortnick A; Allman D
J Immunol; 2013 Jun; 190(12):5913-8. PubMed ID: 23749966
[TBL] [Abstract][Full Text] [Related]
47. miRNA meets plasma cells "How tiny RNAs control antibody responses".
Meinzinger J; Jäck HM; Pracht K
Clin Immunol; 2018 Jan; 186():3-8. PubMed ID: 28736279
[TBL] [Abstract][Full Text] [Related]
48. The stressful road to antibody secretion.
Ma Y; Hendershot LM
Nat Immunol; 2003 Apr; 4(4):310-1. PubMed ID: 12660729
[No Abstract] [Full Text] [Related]
49. The therapeutic potential of targeting CD40-TRAF6 pathway in cardiovascular diseases.
Zhong P; Chen M; Kong B; Fu H; Zhang J; Huang H
Int J Cardiol; 2019 Dec; 297():118. PubMed ID: 31839192
[No Abstract] [Full Text] [Related]
50. Corrigendum to "CD40-miRNA axis controls prospective cell fate determinants during B cell differentiation" [Mol. Immunol. 120 (2020), 46-55].
Salunkhe S; Vaidya T
Mol Immunol; 2021 May; 133():182-183. PubMed ID: 33743267
[No Abstract] [Full Text] [Related]
51. CD9 is a unique marker for marginal zone B cells, B1 cells, and plasma cells in mice.
Won WJ; Kearney JF
J Immunol; 2002 Jun; 168(11):5605-11. PubMed ID: 12023357
[TBL] [Abstract][Full Text] [Related]
52. TRAF6 and TRAF2/3 Binding Motifs in CD40 Differentially Regulate B Cell Function in T-Dependent Antibody Responses and Dendritic Cell Function in Experimental Autoimmune Encephalomyelitis.
Lu Y; Chiang J; Zhang R; Roche PA; Hodes RJ
J Immunol; 2023 Dec; 211(12):1814-1822. PubMed ID: 37921511
[TBL] [Abstract][Full Text] [Related]
53. A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine.
Hermansen JU; Yin Y; Urban A; Myklebust CV; Karlsen L; Melvold K; Tveita AA; Taskén K; Munthe LA; Tjønnfjord GE; Skånland SS
Cell Death Discov; 2023 Apr; 9(1):125. PubMed ID: 37055391
[TBL] [Abstract][Full Text] [Related]
54. Reducing affinity as a strategy to boost immunomodulatory antibody agonism.
Yu X; Orr CM; Chan HTC; James S; Penfold CA; Kim J; Inzhelevskaya T; Mockridge CI; Cox KL; Essex JW; Tews I; Glennie MJ; Cragg MS
Nature; 2023 Feb; 614(7948):539-547. PubMed ID: 36725933
[TBL] [Abstract][Full Text] [Related]
55. Revealing Prognostic and Immunotherapy-Sensitive Characteristics of a Novel Cuproptosis-Related LncRNA Model in Hepatocellular Carcinoma Patients by Genomic Analysis.
Mao Z; Nie Y; Jia W; Wang Y; Li J; Zhang T; Lei X; Shi W; Song W; Zhang X
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672493
[TBL] [Abstract][Full Text] [Related]
56. Mechanisms of CD40-dependent cDC1 licensing beyond costimulation.
Wu R; Ohara RA; Jo S; Liu TT; Ferris ST; Ou F; Kim S; Theisen DJ; Anderson DA; Wong BW; Gershon T; Schreiber RD; Murphy TL; Murphy KM
Nat Immunol; 2022 Nov; 23(11):1536-1550. PubMed ID: 36271147
[TBL] [Abstract][Full Text] [Related]
57. Spatial transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79B mutants-enriched diffuse large B-cell lymphomas.
L'Imperio V; Morello G; Vegliante MC; Cancila V; Bertolazzi G; Mazzara S; Belmonte B; Mangogna A; Balzarini P; Corral L; Lopez G; Di Napoli A; Facchetti F; Pagni F; Tripodo C
Eur J Immunol; 2022 Aug; 52(8):1350-1361. PubMed ID: 35554927
[TBL] [Abstract][Full Text] [Related]
58. Patient-Specific Modeling of Diffuse Large B-Cell Lymphoma.
Thobe K; Konrath F; Chapuy B; Wolf J
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829885
[TBL] [Abstract][Full Text] [Related]
59. System-Level Scenarios for the Elucidation of T Cell-Mediated Germinal Center B Cell Differentiation.
Verstegen NJM; Ubels V; Westerhoff HV; van Ham SM; Barberis M
Front Immunol; 2021; 12():734282. PubMed ID: 34616402
[TBL] [Abstract][Full Text] [Related]
60. TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity.
Yu X; James S; Felce JH; Kellermayer B; Johnston DA; Chan HTC; Penfold CA; Kim J; Inzhelevskaya T; Mockridge CI; Watanabe Y; Crispin M; French RR; Duriez PJ; Douglas LR; Glennie MJ; Cragg MS
Commun Biol; 2021 Jun; 4(1):772. PubMed ID: 34162985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
